Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases.

Ortuño Sahagún D, Márquez-Aguirre AL, Quintero-Fabián S, López-Roa RI, Rojas-Mayorquín AE.

PPAR Res. 2012;2012:318613. doi: 10.1155/2012/318613. Epub 2012 Nov 28.

2.

Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists.

Bassaganya-Riera J, Guri AJ, Hontecillas R.

J Obes. 2011;2011:897894. doi: 10.1155/2011/897894. Epub 2010 Dec 28.

3.

Role of PPAR in cardiovascular diseases.

Das SK, Chakrabarti R.

Recent Pat Cardiovasc Drug Discov. 2006 Jun;1(2):193-209. Review.

PMID:
18221086
4.

Safety issues and prospects for future generations of PPAR modulators.

Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B.

Biochim Biophys Acta. 2007 Aug;1771(8):1065-81. Epub 2007 Feb 24. Review.

PMID:
17428730
5.

Evolution of peroxisome proliferator-activated receptor agonists.

Chang F, Jaber LA, Berlie HD, O'Connell MB.

Ann Pharmacother. 2007 Jun;41(6):973-83. Epub 2007 May 22. Review.

PMID:
17519293
7.

Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma.

Fakhrudin N, Ladurner A, Atanasov AG, Heiss EH, Baumgartner L, Markt P, Schuster D, Ellmerer EP, Wolber G, Rollinger JM, Stuppner H, Dirsch VM.

Mol Pharmacol. 2010 Apr;77(4):559-66. doi: 10.1124/mol.109.062141. Epub 2010 Jan 11.

9.
10.

Peroxisome proliferator-activated receptor (PPAR) gamma agonists as therapeutic agents for cardiovascular disorders: Focus on atherosclerosis.

Ivanova EA, Myasoedova VA, Melnichenko AA, Orekhov AN.

Curr Pharm Des. 2016 Nov 18. [Epub ahead of print]

PMID:
27855608
11.

Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.

Cho MC, Lee K, Paik SG, Yoon DY.

PPAR Res. 2008;2008:679137. doi: 10.1155/2008/679137.

12.
13.
14.
15.

Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.

Panunti B, Fonseca V.

Vascul Pharmacol. 2006 Jul;45(1):29-35. Epub 2006 Jun 14. Review.

PMID:
16777491
16.

Mitochondrial biogenesis: pharmacological approaches.

Valero T.

Curr Pharm Des. 2014;20(35):5507-9.

PMID:
24606795
17.

The need for physiologically relevant peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands.

Subramani PA, Reddy MC, Narala VR.

Endocr Metab Immune Disord Drug Targets. 2013 Jun;13(2):175-83. Review.

PMID:
23713695
19.

Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.

Hsu WH, Chen TH, Lee BH, Hsu YW, Pan TM.

Food Chem Toxicol. 2014 Feb;64:94-103. doi: 10.1016/j.fct.2013.11.015. Epub 2013 Nov 22.

PMID:
24275089
20.

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.

O'Sullivan SE.

Br J Pharmacol. 2007 Nov;152(5):576-82. Epub 2007 Aug 20. Review.

Supplemental Content

Support Center